Beta

    fda approve gedatolisib for advanced breast cancer

    Before Aug 1, 2026

    fda approve gedatolisib for advanced breast cancer. Best Yes near 70¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 70¢ · Best No: 37¢ · 1 platform

    • Kalshi: Yes 70¢ / No 37¢
    LIVE

    Before Aug 1, 2026

    Volume

    $3.4K

    $304 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Aug 1, 2026

    ~46 days left

    Category

    Culture

    70¢CHANCE OF YES65%35%
    Yes
    70¢
    Kalshi
    No
    37¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    KalshiKalshi
    Best Yes
    Best No
    Yes
    70¢
    No
    37¢
    Vol
    $3.4K
    $304 24h
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Aug 1, 2026, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 70¢: exit costs ~1.47¢/contract
    Full calculator

    Market Details

    ResolutionResolves Aug 1, 2026
    Time Left46 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In